Voyageur Pharmaceuticals (VM) Ratios

20 Followers

Voyageur Pharmaceuticals Ratios

TSE:VM's free cash flow for Q4 2025 was C$-1.32K. For the 2025 fiscal year, TSE:VM's free cash flow was decreased by C$ and operating cash flow was C$-1.35K. See a summary of the company’s cash flow.

Ratios	TTM	Feb 26	Feb 25	Feb 24	Feb 23
Liquidity Ratios
Current Ratio	―	0.33	0.17	0.13	0.27
Quick Ratio	―	0.30	0.14	0.12	0.25
Cash Ratio	―	0.15	0.08	<0.01	0.05
Solvency Ratio	―	-1.91	-0.79	-1.92	-2.78
Operating Cash Flow Ratio	―	-1.60	-0.14	-1.47	-2.91
Short-Term Operating Cash Flow Coverage	―	0.00	0.00	0.00	0.00
Net Current Asset Value	C$ ―	C$ -1.26M	C$ -1.79M	C$ -639.25K	C$ -473.65K
Leverage Ratios
Debt-to-Assets Ratio	―	0.01	0.02	0.02	0.01
Debt-to-Equity Ratio	―	0.03	0.09	0.03	0.02
Debt-to-Capital Ratio	―	0.03	0.08	0.03	0.02
Long-Term Debt-to-Capital Ratio	―	0.03	0.08	0.03	0.02
Financial Leverage Ratio	―	2.48	5.77	1.51	1.43
Debt Service Coverage Ratio	―	0.00	0.00	0.00	0.00
Interest Coverage Ratio	―	0.00	0.00	0.00	0.00
Debt to Market Cap	―	<0.01	<0.01	<0.01	<0.01
Interest Debt Per Share	―	<0.01	<0.01	<0.01	<0.01
Net Debt to EBITDA	―	0.06	0.07	-0.03	<0.01
Profitability Margins
Gross Profit Margin	―	-10466.55%	0.00%	0.00%	0.00%
EBIT Margin	―	-30231.56%	0.00%	0.00%	0.00%
EBITDA Margin	―	-30221.87%	0.00%	0.00%	0.00%
Operating Profit Margin	―	-30231.56%	0.00%	0.00%	0.00%
Pretax Profit Margin	―	-30231.56%	0.00%	0.00%	0.00%
Net Profit Margin	―	-30231.56%	0.00%	0.00%	0.00%
Continuous Operations Profit Margin	―	-30231.56%	0.00%	0.00%	0.00%
Net Income Per EBT	―	100.00%	100.00%	100.00%	100.00%
EBT Per EBIT	―	100.00%	100.47%	114.62%	100.23%
Return on Assets (ROA)	―	-113.77%	-65.70%	-64.68%	-83.70%
Return on Equity (ROE)	―	-282.05%	-379.42%	-97.47%	-119.75%
Return on Capital Employed (ROCE)	―	-273.32%	-337.19%	-81.95%	-116.35%
Return on Invested Capital (ROIC)	―	-273.32%	-337.19%	-81.95%	-116.35%
Return on Tangible Assets	―	-113.77%	-65.70%	-64.68%	-83.70%
Earnings Yield	―	-12.92%	-19.08%	-26.81%	-23.24%
Efficiency Ratios
Receivables Turnover	―	0.09	0.00	0.00	0.00
Payables Turnover	―	0.85	<0.01	0.01	<0.01
Inventory Turnover	―	25.11	0.02	0.21	0.28
Fixed Asset Turnover	―	3.74	0.00	0.00	0.00
Asset Turnover	―	<0.01	0.00	0.00	0.00
Working Capital Turnover Ratio	―	>-0.01	0.00	0.00	0.00
Cash Conversion Cycle	―	3.77K	-195.79K	-34.69K	-72.92K
Days of Sales Outstanding	―	4.19K	0.00	0.00	0.00
Days of Inventory Outstanding	―	14.54	15.54K	1.72K	1.30K
Days of Payables Outstanding	―	430.08	211.33K	36.42K	74.22K
Operating Cycle	―	4.20K	15.54K	1.72K	1.30K
Cash Flow Ratios
Operating Cash Flow Per Share	―	-0.02	>-0.01	>-0.01	-0.02
Free Cash Flow Per Share	―	-0.02	>-0.01	>-0.01	-0.02
CapEx Per Share	―	<0.01	0.00	<0.01	<0.01
Free Cash Flow to Operating Cash Flow	―	1.00	1.00	1.00	1.16
Dividend Paid and CapEx Coverage Ratio	―	-578.56K	0.00	-5.67K	-6.08
Capital Expenditure Coverage Ratio	―	-578.56K	0.00	-5.67K	-6.08
Operating Cash Flow Coverage Ratio	―	-72.32	-7.56	-24.78	-67.35
Operating Cash Flow to Sales Ratio	―	-247.56	0.00	0.00	0.00
Free Cash Flow Yield	―	-10.58%	-3.38%	-18.99%	-26.52%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-7.74	-5.24	-3.73	-4.30
Price-to-Sales (P/S) Ratio	―	2.34K	0.00	0.00	0.00
Price-to-Book (P/B) Ratio	―	21.82	19.88	3.64	5.15
Price-to-Free Cash Flow (P/FCF) Ratio	―	-9.45	-29.59	-5.27	-3.77
Price-to-Operating Cash Flow Ratio	―	-9.45	-29.59	-5.27	-4.39
Price-to-Earnings Growth (PEG) Ratio	―	-0.11	-0.33	0.11	0.17
Price-to-Fair Value	―	21.82	19.88	3.64	5.15
Enterprise Value Multiple	―	-7.68	-5.17	-4.31	-4.31
Enterprise Value	―	27.11M	8.82M	5.26M	7.54M
EV to EBITDA	―	-7.68	-5.17	-4.31	-4.31
EV to Sales	―	2.32K	0.00	0.00	0.00
EV to Free Cash Flow	―	-9.37	-29.18	-5.30	-3.77
EV to Operating Cash Flow	―	-9.37	-29.18	-5.30	-4.39
Tangible Book Value Per Share	―	<0.01	<0.01	0.01	0.01
Shareholders’ Equity Per Share	―	<0.01	<0.01	0.01	0.01
Tax and Other Ratios
Effective Tax Rate	―	0.00	0.00	0.00	>-0.01
Revenue Per Share	―	<0.01	0.00	0.00	0.00
Net Income Per Share	―	-0.02	-0.01	-0.01	-0.02
Tax Burden	―	1.00	1.00	1.00	1.00
Interest Burden	―	1.00	1.00	1.14	1.00
Research & Development to Revenue	―	77.68	0.00	0.00	0.00
SG&A to Revenue	―	119.97	0.00	0.00	0.00
Stock-Based Compensation to Revenue	―	0.00	0.00	0.00	0.00
Income Quality	―	0.82	0.18	0.71	0.98

Currency in CAD